Analysis of the prostate cancer incidence and mortality as a basis to optimize medical care in the Moscow Region

Cover Page

Cite item


Background: Prostate cancer (PC) is one of the most commonly diagnosed tumors in the male population that makes relevant to study current trends of its incidence and related mortality.

Aim: To identify current trends in РС incidence and mortality in the Moscow Region.

Materials and methods: To analyze the PC incidence and mortality in the Moscow Region from 2011 to 2016, we used data extracted from the annual report forms of the federal statistic surveillance of the public healthcare and from the Moscow Regional Cancer Registry that contains regional information on newly diagnosed cancers.

Results: From 2011 to 2015, the number of PC cases in men living in the Moscow Region has increased by 38%, with an average annual growth of the incidence by 8.8%. In 2016, there was a 8.7% decline in the new PC cases (in total, 1765), compared to that in 2015. From 2011 to 2015, the incidence of PC has increased from 42.5 to 57.8 per 100,000, primarily due to its change in men above their 50 years of age. In 2016, the PC incidence went down to 52.2 per 100,000. The peak PC incidence in all years of the study was in the age group of 70 to 79 years. In 2016, there was a non-significant decrease in PC-related mortality to 16.6 per 100,000.

Conclusion: The results obtained can be used to optimize medical care for PC patients in the Moscow Region.

About the authors

A. S. Balkanov

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.

Andrey S. Balkanov – MD, PhD, Head of Department of Radiology.

61/2–7 Shchepkina ul., Moscow, 129110, +7 (495) 681 19 07

Russian Federation

V. V. Bazaev

Moscow Regional Research and Clinical Institute (MONIKI)


Vladimir V. Bazaev – MD, PhD, Professor, Head of Department of Urology.

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

A. N. Gurov

Moscow Regional Research and Clinical Institute (MONIKI)


Andrey N. Gurov – MD, PhD, Professor, Head of Department of Science and Organization

61/2 Shchepkina ul., Moscow, 129110

Russian Federation


  1. Hassanipour-Azgomi S, Mohammadian-Hafshejani A, Ghoncheh M, Towhidi F, Jamehshorani S, Salehiniya H. Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide. Prostate Int. 2016;4(3): 118– 24. doi: 10.1016/j.prnil.2016.07.001.
  2. Гуров АН, Балканов АС, Катунцева НА, Огнева ЕЮ. Анализ онкозаболеваемости и смертности населения Московской области за 2014 год. Альманах клинической медицины. 2015;(41): 6–11. doi: 10.18786/20720505-2015-41-6-11.
  3. Ondrusova M, Ondrus D, Karabinos J, Muzik J, Kliment J, Gulis G. Trends in prostate cancer incidence and mortality before and after the introduction of PSA testing in the Slovak and Czech Republics. Tumori. 2011;97(2): 149–55. doi: 10.1700/667.7775.
  4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2): 74–108. doi: 10.3322/canjclin.55.2.74.
  5. Gilbert SM, Pow-Sang JM, Xiao H. Geographical factors associated with health disparities in prostate cancer. Cancer Control. 2016;23(4): 401–8. doi: 10.1177/107327481602300411.
  6. Pakzad R, Mohammadian-Hafshejani A, Ghoncheh M, Pakzad I, Salehiniya H. The incidence and mortality of prostate cancer and its relationship with development in Asia. Prostate Int. 2015;3(4): 135–40. doi: 10.1016/j.prnil.2015.09.001.
  7. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986– 2005. J Natl Cancer Inst. 2009;101(19): 1325–9. doi: 10.1093/jnci/djp278.
  8. Helgstrand JT, Røder MA, Klemann N, Toft BG, Brasso K, Vainer B, Iversen P. Diagnostic characteristics of lethal prostate cancer. Eur J Cancer. 2017;84:18–26. doi: 10.1016/j.ejca.2017.07.007.
  9. Chirpaz E, Colonna M, Menegoz F, Grosclaude P, Schaffer P, Arveux P, Lesec'h JM, Exbrayat C, Schaerer R. Incidence and mortality trends for prostate cancer in 5 French areas from 1982 to 1996. Int J Cancer. 2002;97(3): 372–6. doi: 10.1002/ijc.1603.
  10. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2): 87–108. doi: 10.3322/caac.21262.
  11. Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T, Dicker A, Wender R. Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol. 2011;18(5): 5875–83.
  12. Bratt O, Garmo H, Adolfsson J, Bill-Axelson A, Holmberg L, Lambe M, Stattin P. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. J Natl Cancer Inst. 2010;102(17): 1336–43. doi: 10.1093/jnci/djq265.
  13. D'Amico AV, Chen MH, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2015;314(12): 1291–3. doi: 10.1001/jama.2015.8577.
  14. Turk H, Celik O, Un S, Yoldas M, İsoglu CS, Karabicak M, Ergani B, Koc G, Zorlu F, Ilbey YO. Predictive factors for biochemical recurrence in radical prostatectomy patients. Cent European J Urol. 2015;68(4): 404–9. doi: 10.5173/ceju.2015.606.
  15. Kotwal AA, Schonberg MA. Cancer screening in the elderly: a review of breast, colorectal, lung, and prostate cancer screening. Cancer J. 2017;23(4): 246–53. doi: 10.1097/PPO.0000000000000274.

Supplementary files

There are no supplementary files to display.

Copyright (c) 2018 Balkanov A.S., Bazaev V.V., Gurov A.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies